stonks4u
Sign up free
MYGN logo

MYGN Myriad Genetics, Inc.

NASDAQ · Medical - Diagnostics & Research · Healthcare

$3.03
-0.14 (-4.42%)

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovari…

Market Cap: $286.18Mwww.myriad.com

Price (90d)

$3.26
$2.86$4.01$5.16$6.31
Apr 30Aug 7

Signal Score (90d)

50
506783100
Aug 8Aug 13

Quote

Day Range
$3.02 – $3.18
52-Week Range
$2.74 – $8.59
Volume
$1.55M
Market Cap
$286.18M
50-Day Avg
$4.89
200-Day Avg
$5.38
Prev Close
$3.17
Open
$3.16

Valuation & Ratios

P/E Ratio
-1.55
EPS
$-3.92
P/B Ratio
1.56
P/S Ratio
0.70
Debt/Equity
0.57
Current Ratio
2.49
Dividend Yield
+0.0%
Gross Margin
+69.9%

Returns & Efficiency

Return on Equity
-99.4%
Return on Assets
-51.8%
FCF Yield
-4.5%
EV/EBITDA
-1.92

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$824.50M$-365.90M$-3.96
2024$837.60M$-127.30M$-1.41
2023$753.20M$-263.30M$-3.18
2022$678.40M$-112.00M$-1.39
2021$690.60M$-27.20M$-0.35

Social Signal Score

38
5d
50
1 mentions
+0.0%
30d
34
4 mentions
-47.3%
60d
34
4 mentions
-23.3%
90d
34
4 mentions
-8.9%
news: 4

Earnings

Mon, Nov 2(in 3 months)

Consensus estimate $-0.16 per share

4of 7 quarters beat consensus

Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Jul 30$-0.25 vs $-0.06miss
  • Tue, May 5$-0.09 vs $-0.06miss
  • Mon, Feb 23$0.04 vs $-0.02beat
  • Mon, Nov 3$-0.13 vs $-0.01miss
  • Tue, Aug 5$0.05 vs $-0.01beat
  • Tue, May 6$-0.03 vs $-0.05beat

Estimates and results for MYGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

MYGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (4)

  • Newsbusinesswire.com·1d ago·Neutral

    MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations NEW YORK--(BUSINESS WIRE)---- $MYGN #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlaw…

    View source ↗
  • Newsprnewswire.com·5d ago·Positive

    Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors.

    View source ↗
  • Newsgurufocus.com·7d ago·Negative

    MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law [url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv

    View source ↗
  • Newsbusinesswire.com·7d ago·Negative

    MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law.

    View source ↗